PBAC
High-dose PPI changes ‘effective’: PBAC
Decrease in esomeprazole and increase in pantoprazole scripts likely due to restriction changes, says PBAC, though full picture obscured by lack of OTC and private data Restriction changes established in …
A new recommendation
PBAC recommends listing of adalimumab biosimilar The PBAC has recommended the Authority Required listing of adalimumab (Yuflyma) in the form of 40 mg in 0.4 mL pre-filled syringe and pre-filled …
High doses drop after moves to curb overprescribing
Patients have been shifting to lower dose PPIs following PBS listing changes, review reveals, but more investigation is needed The Drug Utilisation Sub-Committee (DUSC) of the PBAC has found positive …
Keeping up with biosimilars
Pharmacy has a prominent role in the supply and provision of biosimilar medicines, and the profession has been slow to come to terms with this. Is the situation now changing? …
Extended prescribing impasse
Mixed messages from the Department of Health over two-month prescriptions, as new documents say pharmacist mark-ups will impact consumer and taxpayer savings New Department of Health documents reveal that two-month …
‘Jobs will be lost.’
Pharmacy group estimates average loss of $85k in gross profit per pharmacy if 60-day dispensing proposal goes forward With the 60-day dispensing proposal still on the table, the Rural Pharmacy …
Dosing on the agenda
Decision on PPI double dosing deferred by PBAC, but support given to antibiotic listing changes The Pharmaceutical Benefits Advisory Committee (PBAC) has deferred a decision on whether to allow twice …
Still on the wish list
Are two month prescriptions back on the government’s agenda? Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) that prescription lengths be doubled to two months for a range of medicines …
Keeping up to date
PBAC reveals the latest raft of new recommendations made on PBS drugs The latest recommendations made by the Pharmaceutical Benefits Advisory Committee have been released, with new listings for naloxone …
Blockbuster alert
Nine new blockbuster drugs headed our way soon: report A series of new ‘blockbuster’ drugs are expected to hit Australian shores in the next 12-24 months, a new report claims. …
PrEP listing decision deferred
An HIV prevention advocate has vowed to keep fighting for pre exposure prophylaxis to be PBS listed Following the announcement by the Pharmaceutical Benefits Advisory Committee that it will defer …
CHF get a new seat on PBAC
Consumers’ group deputy head now gains a senior role on key PBS committee Federal Health Minister Greg Hunt has announced that Jo Watson, deputy chair of the Consumers Health Forum …